Trial reportBMC health services research2026
Prevention of sickness absence through early identification and rehabilitation of at-risk patients with musculoskeletal disorders (PREVSAM): a cost-effectiveness analysis comparing team-based rehabilitation in primary care vs treatment as usual.
Trial report in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03913325 (Early Identification of Risk for and Prevention of Sickness Absence Due to Musculoskeletal Pain), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Identification of Risk for and Prevention of Sickness Absence Due to Musculoskeletal Pain (PREVSAM) - a Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe PREVention of Sickness Absence through early identification and rehabilitation of at-risk patients with Musculoskeletal disorders (PREVSAM) model for team-based rehabilitation in primary care of patients with higher risk for sickness absence was investigated in a randomised controlled trial. Participants were screened with the Örebro Musculoskeletal Pain Screening Questionnaire - short form using a minimum value of 40 points for inclusion in the trial.
methodsThis cost-effectiveness analysis (CEA) was performed alongside the PREVSAM trial from both healthcare and societal perspectives regarding costs in relation to change in quality-adjusted life-years (QALYs) over one year for groups receiving care according to the PREVSAM model and treatment as usual.
resultsBoth team-based rehabilitation and treatment as usual led to similar QALYs over one year. From the healthcare perspective, the PREVSAM model was somewhat more costly, with higher rehabilitation costs not being fully outweighed by lower costs for other primary care, specialised care, and medication. From the societal perspective, there was essentially no difference in total costs, as lower production loss costs essentially compensated for the higher rehabilitation costs. The probability that the PREVSAM model is cost-effective was close to 50% across conventional Swedish cost-effectiveness thresholds (€43 000 to €86 000 per QALY).
conclusionsThe PREVSAM model and treatment as usual led to similar health outcomes and to similar total societal costs. Neither strategy was shown to be preferable on economic grounds at conventional cost-effectiveness thresholds. High individual variation implies that the screening process needs to be further refined to better identify those patients truly in need of team-based care and to facilitate appropriate resource stratification.
trial registrationThe trial was registered with ClinicalTrials.gov, Protocol ID: NCT03913325. Study Registration Date, First submitted 09/04/2019, First posted 12/04/2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.